Introduction {#Sec1}
============

Approximately 68 million American adults aged 18 years or older (31 % of the total population) have hypertension and thus are at an increased risk for cardiac events \[[@CR1]\]. Notably, hypertension is the most common risk factor for cardiovascular disease (CVD), exceeding diabetes mellitus, obesity, dyslipidemia, and smoking \[[@CR2]\]. Uncontrolled hypertension specifically leads to increased fatal and non-fatal stroke and myocardial infarction (MI), along with heart failure and chronic kidney disease \[[@CR3]\]. With estimated costs exceeding US\$300 billion in 2009, CVD accounts for the single largest proportion of both direct and indirect US health care costs annually \[[@CR2]\]. Furthermore, by 2030, direct medical costs alone are projected to exceed US\$800 billion annually.

A meta-analysis of approximately 1 million adults including 61 prospective observational studies demonstrated an absolute increase in cardiovascular risk that doubles for each 20/10 mmHg increase in systolic/diastolic blood pressure (BP) \[[@CR4], [@CR5]\]. On the other hand, antihypertensive therapy with appropriate reduction in BP has been shown to reduce this increased risk. For each 2-, 3-, and 5-mmHg systolic BP reduction, there is a risk reduction in stroke mortality of 6, 8, and 14 %, respectively, and a risk reduction in coronary heart disease mortality of 4, 5, and 9 %, based upon an analysis of five large population studies \[[@CR6]\].

Unfortunately, over 50 % of patients with hypertension are uncontrolled and, although there has been an increase in improvement of control over the last several years, National Health and Nutrition Examination Survey (NHANES) data have shown that many patients with hypertension remain at increased risk \[[@CR7]\]. Various factors resulting in lack of BP control include the asymptomatic nature of elevated BP in many patients, non-adherence to therapy, and therapeutic inertia. Therefore, achieving adequate BP control involves improved systems for patient adherence, including education and counseling, team-based approaches, and the use of combination therapy with agents from complementary classes, especially in high-risk patients with stage 2 hypertension.

The objective of this article is to discuss racial/ethnic disparities in hypertension, with particular focus on non-white populations including blacks, Hispanics/Latinos, and Asians. In addition, the importance of adherence and persistence with antihypertensive medication and the benefits of single-pill combination (SPC) therapy are described. Clinical trial data on the antihypertensive efficacy and safety of the combination of a dihydropyridine calcium channel blocker and an angiotensin receptor blocker, a widely utilized combination, in the above populations are also presented.

Disparities in Hypertension {#Sec2}
===========================

Cardiovascular risk varies based on race/ethnicity. Although demographic terms are not scientifically based terms, the recognition of differences in hypertension control by race and ethnicity allows clinicians to target populations in need of improved care.

Blacks {#Sec3}
------

African Americans or non-Hispanic blacks have one of the highest rates of hypertension in the world with an increased likelihood of cardiovascular morbidity and mortality \[[@CR2], [@CR8]\]. It is well known that hypertension is perhaps the most significant contributor to the mortality gap between African Americans and white Americans \[[@CR4]\]. Recent NHANES data (2009--2010) showed that the overall age-adjusted prevalence of hypertension in African Americans was approximately 41 % compared with 28 % in non-Hispanic whites \[[@CR9]\]. African Americans develop hypertension more often, at an earlier age, and present with more severe hypertension than whites \[[@CR2], [@CR8]\]. Thus, overall, African Americans have worse BP-related outcomes compared with whites, including greater rates of mortality, stroke, left ventricular hypertrophy, heart failure, chronic kidney disease, and end-stage renal disease \[[@CR2], [@CR8], [@CR10]\].

African Americans also have a high prevalence of obesity, diabetes, and hypercholesterolemia. Analysis of NHANES data showed that age-adjusted rates of obesity increased from 32.0 % (1988--1994) to 42.4 % (1999--2004) among African Americans \[[@CR11]\]. In comparison, non-Hispanic whites had an obesity prevalence of 22.8 and 30.8 % during the same time periods, respectively. The age-adjusted prevalence of diabetes in African Americans increased from 11.5 % in 1988--1994 to 13.0 % in 1999--2004, while that of hypercholesterolemia declined but remained high (from 54.2 to 50.5 %). The presence of comorbid conditions in hypertensive African Americans adds to the difficulty in managing these patients.

Hispanics/Latinos {#Sec4}
-----------------

The term Hispanic is a demographic term for a person of Spanish descent, regardless of race. NHANES primarily studied Mexican Americans and found that, although rates of hypertension were not higher versus whites, this population had the greatest likelihood of not being aware of the presence of hypertension, had less treatment of elevated BP, and had less BP control \[[@CR7], [@CR9], [@CR12]\]. However, according to another recent study, involving middle-aged and older adults aged 45--84 years (mean age 59 years), Carson and colleagues demonstrated that the crude incidence rate of hypertension per 1,000 person-years *was* higher in Hispanics compared with non-Hispanic whites (65.7 vs. 56.8) \[[@CR13]\]. Therefore, the recognition of poorly controlled hypertension across various populations is an important component of decreasing overall CVD and disability in the USA.

The Hispanic Latino population in the USA has increased dramatically over the past few decades, and several studies have demonstrated that this population has a higher cardiovascular risk compared with non-Hispanic whites \[[@CR14], [@CR15]\]. Recently, a multicenter, prospective, population-based study indicated that the prevalence of major cardiovascular risk factors, including hypertension, varies across the diverse Hispanic/Latino backgrounds in the USA. The Hispanic Community Health Study/Study of Latinos included 2,201 Cuban, 1,400 Dominican, 6,232 Mexican, 2,590 Puerto Rican, 1,634 Central American, and 1,022 South American adults aged 18--74 years (mean age 43 years) \[[@CR16]\]. The prevalence of hypertension ranged from 19.9 % (South American) to 32.6 % (Dominican) in men and from 15.9 % (South American) to 29.1 % (Puerto Rican) in women. However, use of antihypertensive medication was low (\~15 %) in both men and women, ranging from 10.7 % (South American) to 18.4 % (Dominican) among men and from 8.4 % (South American) to 18.8 % (Dominican and Puerto Rican) among women. In men and women, high rates of obesity (36.5 and 42.6 %, respectively) and hypercholesterolemia (51.7 and 36.9 %) were noted, and there were positive associations between increased stroke and poorly controlled BP in age-adjusted analyses.

One reason for the disparities noted in the Hispanic/Latino population regarding lack of BP control and lesser awareness and treatment of BP may be the lack of evidence-based guidelines for this minority population \[[@CR17]\]. The Hispanic paradox, despite evidence against it \[[@CR18]\], is another likely contributing factor. As a result, treatment of hypertension may not be taken as seriously in this population. Additionally, given the high prevalence of other cardiovascular risk factors (i.e., obesity, diabetes, hypercholesterolemia, and metabolic syndrome) in the Hispanic/Latino population, these individuals are likely to require multiple agents to adequately control their BP and minimize the risk of cardiovascular complications \[[@CR2], [@CR11]\].

Asians {#Sec5}
------

Asians represent the largest racial group in the world. The prevalence of hypertension in China, the most populated country in the world, has increased rapidly over the past decade, from rates of approximately 20 % in 2000 \[[@CR19]\] to more than one third, based on more recent estimates \[[@CR20]--[@CR23]\]. For example, a cross-sectional study of 5,760 adults in Beijing, China, showed a high prevalence of hypertension (35.5 %), with similar rates in both urban and rural communities \[[@CR21]\]. In Korea, Thailand, and Taiwan, the prevalence of hypertension is lower, but is also expected to increase from 14.5--17.0 % in 2000 to 17.1--18.8 % in 2025 \[[@CR19]\]. In the Beijing study, only 42.5 % of hypertensive patients were aware of their disease, 35.9 % were undergoing treatment, and 11.8 % had their BP controlled \[[@CR21]\]. A similar pattern was reported in other surveys \[[@CR20], [@CR22], [@CR23]\]. These rates are lower than those found among blacks and Mexican Americans, based on recent NHANES data \[[@CR9]\].

As seen in blacks and Hispanics/Latinos, hypertension is often present with other comorbid conditions in the Asian patient. Diabetes, in particular, occurs often in the Asian population, and develops at an earlier age relative to Westerners \[[@CR24]\]. Qin and colleagues \[[@CR25]\] reported that the prevalence of previously undiagnosed diabetes was 9.8 % among 17,184 Chinese hypertensive adults aged 45--75 years; 3.4 % had previously diagnosed diabetes and another 14.1 % had impaired fasting glucose. In another large cross-sectional study, nearly one third of 19,003 adults surveyed in Beijing were overweight or obese and, among obese individuals, the prevalence of hypertension ranged from 34.8 % (body mass index \[BMI\] of 30--34.9 kg/m^2^) to 50.7 % (BMI \>40 kg/m^2^) \[[@CR26]\]. Similar trends were noted for diabetes and metabolic syndrome \[[@CR26]\]. Thus, treatment with a single antihypertensive agent is unlikely to achieve the BP goals for a majority of these high-risk patients.

Implications of Adherence and Persistence to Antihypertensive Therapy {#Sec6}
=====================================================================

Using a hypertension registry at Kaiser Permanente of Northern California, a retrospective analysis of 44,167 adults greater than or equal to 18 years of age (84 % ≤64 years) demonstrated variation in persistence and adherence among sociodemographic groups \[[@CR27]\]. More than 30 % of patients were non-persistent early on (i.e., failed to refill first prescription within 90 days), with one in five non-adherent to therapy (\<80 % of days covered during the 12 months following start of treatment). Suboptimal medication-taking behavior was more likely in non-whites compared with whites. Using regression models for various factors, non-white race was associated with non-persistence (black odds ratio 1.56 \[95 % confidence interval 1.43--1.70\]; Asian 1.40 \[1.29--1.51\]; Hispanic 1.46 \[1.35--1.57\]) and non-adherence (black 1.55 \[1.37--1.77\]; Asian 1.13 \[1.00--1.28\]; Hispanic 1.46 \[1.31--1.63\]). Interestingly, racial/ethnic differences in non-adherence were lessened when medication co-payment and mail-order pharmacy (both aiding ease of use) were factored into the model. These data suggest that health system strategies that reduce patient co-payments, improve access to medications, and optimize the choice of initial therapy may help reduce persistent gaps in the use of clinically effective therapies.

Benefits of Single-Pill Combination Therapy {#Sec7}
===========================================

In view of the high rates of uncontrolled hypertension in African Americans, Hispanics/Latinos, and Asians, optimal therapy along with medication adherence and persistence are important. Evidence suggests that the majority of patients with hypertension will require combination therapy to reach their BP goals \[[@CR4]\]. Antihypertensive regimens that are less complex have been shown to improve medication adherence and persistence \[[@CR28], [@CR29]\]. Combination therapy is appropriate either as an SPC (i.e., multiple agents in a single pill) or free combination (FC) (i.e., multiple agents as separate pills). A study of 7,224 patients demonstrated that SPC therapy over 12 months was associated with better persistence (42.5 % higher; *P* \< 0.002) and adherence (22.1 % higher; *P* \< 0.001) compared with that seen in patients who were switched to FC therapy \[[@CR30]\]. Better adherence and persistence are likely to improve upon positive health benefits through enhanced hypertension control and positive economic benefits through lower costs for hypertension-related health care.

In addition to improved adherence and persistence, combination therapy in the management of hypertension allows for a reduction in BP variability \[[@CR31]\]. Short- and long-term effects of BP variability are associated with an increased risk of both renovascular and cardiovascular events and mortality \[[@CR32]\]. Evidence suggests that combination therapy, particularly the addition of a calcium channel blocker or diuretic to a renin--angiotensin--aldosterone system (RAAS) blocker, is associated with less BP variability, which may improve outcomes \[[@CR31], [@CR33]\]. Furthermore, in a meta-analysis of 42 trials, Wald and colleagues \[[@CR34]\] demonstrated that combining antihypertensive drugs from two different classes lowered BP five times more than doubling the dose of one agent. Of note, given that there are lower dosage requirements in combination therapy for each individual agent and the fact that combination therapy can provide additive or synergistic BP lowering, the result may lead to a reduction in side effects, thus improving compliance \[[@CR33]\]. Therefore, the use of an SPC may translate directly to achievement of BP goals more quickly with attenuation of adverse drug reactions.

SPCs appear to improve compliance especially if differences in acquisition costs can be controlled. In a retrospective cohort study, Malesker and Hilleman \[[@CR35]\] evaluated clinical and economic outcomes in patients using an SPC of amlodipine/valsartan versus the outcomes from conventional combination therapy. In the SPC cohort, 58/100 patients (58 %) achieved BP targets, compared with 47/100 control patients (47 %) (*P* = 0.119), and the absolute reduction in systolic/diastolic BP was significantly greater in the SPC group (22.8 ± 6.9/19.3 ± 5.2 mmHg) than in the control group (20.6 ± 6.4/17.8 ± 5.6 mmHg) (*P* ≤ 0.03). Overall, in the SPC cohort, there were significantly fewer patients who discontinued their antihypertensive therapy because of side effects and non-compliance compared with the control group (both *P* = 0.042). Even though the SPC patients had higher medication acquisition costs (US\$479 vs. US\$367), they accrued fewer clinic visits, laboratory tests, and electrocardiograms, thus translating into a reduction in comprehensive medical treatment costs over the 6 months of follow-up. Specifically, health care resource utilization costs per patient totaled US\$2,734 with the SPC and US\$3,490 in controls (*P* = 0.024). Total health care costs were similarly lowered (16--20 % reduction) with the SPC of amlodipine/valsartan compared with calcium channel blocker/angiotensin receptor blocker FC therapy (*P* \< 0.0001) \[[@CR36]\].

Of note, the cost of SPC therapy to the patient has the potential to be lower since only a single copayment is necessary, compared with multiple copayments for FC therapy \[[@CR37]\]. Lower copayments may have the added benefit of improved adherence and persistence with hypertension medication \[[@CR38]\].

Focus on Combination Amlodipine/Valsartan in Non-Whites with Hypertension {#Sec8}
=========================================================================

Results of several studies suggest that some RAAS-blocking drugs manifest diminished average BP responses in black patients relative to other drug classes (i.e., calcium channel blockers, thiazide diuretics) \[[@CR39]--[@CR41]\]. However, the use of multiple antihypertensive agents has been shown to offset any racial/ethnic differences in response to therapy \[[@CR42]\]. Moreover, RAAS pharmacological blockade provides greater cardiorenal protection than other non-RAAS drug classes \[[@CR43]--[@CR45]\]. A major renoprotective effect is demonstrated with ramipril in African Americans with hypertensive nephropathy, a group at risk for more rapid loss of kidney function over time \[[@CR10], [@CR46]\]. Hispanics/Latinos and Asians with hypertension are also likely to benefit from the use of RAAS inhibitors, especially given that these patients pose a challenge to BP control secondary to their high prevalence of other cardiovascular risk factors such as obesity, diabetes, and metabolic syndrome. Thus, there is a good rationale for the use of RAAS inhibitors as foundation therapy in these high-risk patients, with diuretic or calcium channel blocker added as needed.

Dihydropyridine calcium channel blockers and angiotensin receptor blockers have complementary mechanisms of action (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR47]\], and each of these drug classes is recommended in the prevention and/or treatment of most complications of hypertension (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR48]\]. The following sections and Table [1](#Tab1){ref-type="table"} summarize the results of studies with combination amlodipine/valsartan in non-white populations with hypertension, with a focus on blacks, Hispanics/Latinos, and Asians. Since these drugs are widely utilized in the USA in hypertension pharmacotherapy, these particular agents, representing the dihydropyridine calcium channel blocker and angiotensin receptor blocker drug classes, will be the main focus of discussion. Both valsartan and amlodipine have been extensively studied, with a wealth of BP and outcomes data \[[@CR49]--[@CR52]\].Fig. 1Complementary mechanisms of action (MOA) of dihydropyridine calcium channel blockers (CCBs) and angiotensin receptor blockers (ARBs) in lowering blood pressure (BP). Reprinted from Neutel \[[@CR47]\], with permission from JTE MultimediaFig. 2Conditions favoring the use of dihydropyridine calcium channel blockers (CCBs) and angiotensin receptor blockers (ARBs) according to guidelines for the management of hypertension. Reprinted with permission of Dove Medical Press Ltd, from Waeber and Ruilope \[[@CR48]\]; permission conveyed through Copyright Clearance Center, IncTable 1Overview of studies with combination amlodipine/valsartan in non-white hypertensive populationsAuthorStudy populationDesignTreatment groupsEfficacySafetySub-Saharan African blacks Odili et al. \[[@CR53]\]*N* = 140 sub-Saharan African patients with BP 140--179/90--109 mmHg and ≤2 additional risk factors6-month, multicenter, randomized, open-label (blinded assessment of BP)Amlodipine/valsartan 5/160 mg; bisoprolol/HCTZ 5/6.25 mg. Amlodipine and bisoprolol doses doubled to achieve BP \<140/90 mmHg, along with the possible addition of α-methyldopaMean BP reductions from baseline in the combined treatment groups were 18.2/10.1 mmHg at week 2, 19.4/11.2 mmHg at week 4, 22.4/12.2 mmHg at week 8, and 25.8/15.2 mmHg at week 12. BP \<140/90 mmHg: \>65 % by week 2 in the combined treatment groupsDiscontinuations due to AEs: 1 patient (1.4 %) in each group. Study medication adjusted in 3 patients because of heartburn, tiredness, and diarrhea (treatment group not specified)Black populations in the USA Flack et al. \[[@CR54]\]*N* = 572 black patients with MSSBP 160--199 mmHg12-week, multicenter, randomized, double-blindAmlodipine/valsartan 5/160 mg × 2 weeks uptitrated to 10/160 mg × 2 weeks with optional titration at week 4 to 10/320 mg if MSSBP ≥130 mmHg; amlodipine 5 mg × 2 weeks uptitrated to 10 mg × 10 weeks. In both arms, HCTZ 12.5 mg could be added at 8 weeks if MSSBP ≥130 mmHgLSM MSSBP/MSDBP reductions from baseline to week 8: 33.3/13.6 mmHg with amlodipine/valsartan vs. 26.6/10.8 mmHg with amlodipine (*P* \< 0.0001/*P* \< 0.001). MSSBP/MSDBP \<140/90 mmHg at week 8: 49.8 vs. 30.2 % (*P* \< 0.0001)Any AE during study: 44.4 % with amlodipine/valsartan vs. 45.3 % with amlodipine. Most common AEs were peripheral edema (12.6 vs. 9.5 %), headache (4.2 vs. 5.3 %), and dizziness (2.4 vs. 2.5 %). Discontinuations due to AEs: 2.4 vs. 3.2 % Smith et al. \[[@CR55]\]Subgroup analysis of 2 studies of 3,161 patients with MSDBP 95--109 mmHg, including 2,508 white and 201 black8-week, multicenter, randomized, double-blind, placebo-controlledPlacebo; amlodipine 2.5 mg, 5 mg, or 10 mg; valsartan 40 mg, 80 mg, 160 mg, or 320 mg; amlodipine/valsartan 2.5/40 mg, 2.5/80 mg, 2.5/160 mg, 2.5/320 mg, 5/40 mg, 5/80 mg, 5/160 mg, 5/320 mg, 10/160 mg, or 10/320 mg. Note: results for two highest combination dose groups not reported in blacks because of limited sample sizeLSM MSSBP/MSDBP reductions from baseline to week 8: white: 15.7/10.7 mmHg with amlodipine/valsartan 2.5/40 mg to 23.0/15.5 mmHg with amlodipine/valsartan 5/320 mg; black: 16.5/7.7 mmHg with amlodipine/valsartan 2.5/40 mg to 17.5/17.9 mmHg with amlodipine/valsartan 5/320 mg. In both white and black patients, greater BP reductions were observed in each of the combination therapy groups compared with the respective monotherapies or placeboAny AE during study: white: 41.5 % with any amlodipine/valsartan combination, 43.6 % with amlodipine, 37.3 % with valsartan, and 34.0 % with placebo; black: 54.1 % with any amlodipine/valsartan combination, 51.7 % with amlodipine, 47.5 % with valsartan, and 61.5 % with placebo. Most common AEs with any amlodipine/valsartan combination: white: peripheral edema (5.0 vs. 2.6 % placebo), nasopharyngitis (4.0 vs. 1.9 %), headache (3.6 vs. 6.0 %), and upper respiratory tract infection (2.3 vs. 1.1 %); black: nasopharyngitis (9.2 vs. 7.7 %), upper respiratory tract infection (7.1 vs. 7.7 %), headache (6.1 vs. 7.7 %), and peripheral edema (5.1 vs. 15.4 %) Ofili et al. \[[@CR42]\]Post hoc analysis of 728 patients who were treatment naïve or not responding to ARB monotherapy (other than valsartan) for ≥4 weeks (MSSBP 150--199 mmHg), including 474 white, 198 African American, and 165 Hispanic12-week, multicenter, randomized, double-blindModerate treatment: amlodipine/valsartan 5/160 mg × 4 weeks uptitrated to amlodipine/valsartan/HCTZ 5/160/12.5 mg × 8 weeks; intensive treatment: amlodipine/valsartan 5/320 mg × 2 weeks uptitrated to amlodipine/valsartan 10/320 mg × 2 weeks uptitrated to amlodipine/valsartan/HCTZ 10/320/12.5 mg × 8 weeks. In both arms, another 12.5 mg of HCTZ could be added at 8 weeks if MSSBP \>140 mmHgLSM MSSBP reductions from baseline to week 4: white: 19.0 mmHg with moderate treatment vs. 23.5 mmHg with intensive treatment (*P* \< 0.001); African American: 18.1 vs. 20.4 mmHg (*P* = NS); Hispanic: 17.5 vs. 23.4 mmHg. MSSBP/MSDBP \<140/90 mmHg at week 4: white: 30.5 vs. 44.7 % (*P* \< 0.01); African American: 26.9 vs. 37.1 % (*P* \< 0.05); Hispanic: 33.3 vs. 54.8 % (*P* \< 0.01)Any AE during study: white: 38.3 % with moderate treatment vs. 37.7 % with intensive treatment; African American: 35.1 vs. 36.2 %; Hispanic: 23.5 vs. 22.4 %. Most common AEs were peripheral edema (white: 5.8 vs. 11.0 %; African American: 2.1 vs. 3.8 %; Hispanic: 2.5 vs. 8.2 %), dizziness (white: 4.6 vs. 4.2 %; African American: 2.1 vs. 6.7 %; Hispanic: 2.5 vs. 2.4 %), and headache (white: 2.1 vs. 2.9 %; African American: 3.8 vs. 3.2 %; Hispanic: 2.4 vs. 4.9 %)Hispanics/Latinos Destro et al. \[[@CR59]\]*N* = 646 patients with MSSBP 160--199 mmHg, including 224 Hispanic/Latino and 33 black8-week, multicenter, randomized, double-blindAmlodipine/valsartan 5/160 mg × 2 weeks uptitrated to 10/160 mg × 6 weeks; amlodipine 5 mg × 2 weeks uptitrated to 10 mg × 6 weeks. In both arms, HCTZ could be added at 4 weeks if MSSBP ≥130 mmHgLSM MSSBP reductions from baseline to week 4: overall: 30.1 mmHg with amlodipine/valsartan vs. 23.5 mmHg with amlodipine (*P* \< 0.0001); Hispanic/Latino: 29.1 vs. 23.0 mmHg (*P* \< 0.05); black: 30.4 vs. 25.1 mmHg (*P* = NS). MSSBP \<140 mmHg at week 4: overall: 51.8 vs. 27.7 %; Hispanic/Latino: 55.1 vs. 35.8 %; black: 50.0 vs. 45.5 %Any AE during study (results not provided by race/ethnicity): 35.2 % with amlodipine/valsartan vs. 37.2 % with amlodipine. Most common AEs were peripheral edema (12.8 vs. 17.6 %) and headache (3.7 vs. 3.1 %). Discontinuations due to AEs: 5.9 vs. 5.9 % Ofili et al. \[[@CR42]\]See results for Hispanic population under "Black populations in the USA"Asians Chazova et al. \[[@CR56]\]*N* = 2,729 patients with BP \>140/90 mmHg, including 1,478 Asian12-week, multicenter, open-label, observational, non-interventional, surveillanceAmlodipine/valsartan 5/80 mg, 10/80 mg, 5/160 mg, or 10/160 mgMean BP reductions from baseline to week 12: 29.2/15.1 mmHg with 5/80 mg, 36.0/16.7 mmHg with 10/80 mg, 39.9/19.4 mmHg with 5/160 mg, and 43.6/22.4 mmHg with 10/160 mg. BP \<140/90 mmHg during study: 75.6 %Any AE during study: 8.8 % across groups. Most common AEs were edema (2.3 %) and dizziness (1.4 %) Ke et al. \[[@CR57]\]*N* = 698 Asian patients not responding to amlodipine 5-mg monotherapy × 4 weeks (MSDBP 90--109 mmHg), including 601 Chinese8-week, multicenter, randomized, double-blindAmlodipine/valsartan 5/80 mg; amlodipine 5 mgLSM MSSBP/MSDBP reductions from baseline to week 8: 11.4/9.7 mmHg with amlodipine/valsartan vs. 7.4/7.1 mmHg with amlodipine (*P* \< 0.0001). MSSBP/MSDBP \<140/90 mmHg at week 8: 69.2 vs. 57.6 % (*P* = 0.0013)Any AE during study: 25.2 % with amlodipine/valsartan vs. 24.6 % with amlodipine. Most common AEs were hyperlipidemia (4.3 vs. 3.2 %) and dizziness (2.9 vs. 2.0 %). Discontinuations due to AEs: 2.9 vs. 2.0 % Huang et al. \[[@CR58]\]*N* = 918 Asian patients not responding to valsartan 80-mg monotherapy × 4 weeks (MSDBP 90--109 mmHg), including 813 Chinese8-week, multicenter, randomized, double-blindAmlodipine/valsartan 5/80 mg; valsartan 80 mg; valsartan 160 mgLSM MSSBP/MSDBP reductions from baseline to week 8: 12.5/10.8 mmHg with amlodipine/valsartan vs. 6.0/6.3 mmHg with valsartan 80 mg and 7.7/7.2 mmHg with valsartan 160 mg (both *P* \< 0.0001). MSSBP/MSDBP \<140/90 mmHg at week 8: 70.5 vs. 44.1 % and 58.6 % (both *P* \< 0.01)Any AE during study: 22.1 % with amlodipine/valsartan vs. 18.2 % with valsartan 80 mg and 20.8 % with valsartan 160 mg. Most common AEs were hyperlipidemia (2.9 vs. 4.2 % and 5.0 %), dizziness (1.6 vs. 1.0 % and 2.0 %), and hyperuricemia (1.9 vs. 2.0 % and 0.3 %). Discontinuations due to AEs: 1.9 vs. 0 % and 1.7 %*AE* adverse event, *ARB* angiotensin receptor blocker, *BP* blood pressure, *HCTZ* hydrochlorothiazide, *LSM* least-squares mean, *MSDBP* mean sitting diastolic blood pressure, *MSSBP* mean sitting systolic blood pressure, *NS* not significant

A search of PubMed was conducted through to 25 February 2013, using the title/abstract key words (amlodipine AND valsartan AND \[hypertension OR hypertensive\] AND \[black(s) OR African American(s) OR Hispanic(s) OR Latino(s) OR Mexican(s) OR Asian(s)\]). This search revealed a total of 19 articles in the English language. A review of the abstracts from this search identified a total of seven studies that included an efficacy and/or safety evaluation of combination amlodipine/valsartan in the non-white populations of interest \[[@CR42], [@CR53]--[@CR58]\]. The authors were aware of and included an additional study that was not identified in the PubMed search \[[@CR59]\]. In total, these studies comprised 1,111 black, 389 Hispanic/Latino, and 3,094 Asian patients with hypertension.

Sub-Saharan African Blacks {#Sec9}
--------------------------

Even though hypertension hardly existed in black Africa in the first half of the 20th century \[[@CR60]\], more recently, in those aged 65 years and over, hypertension has been shown to affect 30--60 % of African blacks \[[@CR61]\]. Moreover, this proportion is steadily approaching the 60--70 % range in the USA for blacks of similar age \[[@CR61]\]. Thus, reducing BP and controlling hypertension are critical factors in preventing CVD.

In the Newer versus Older Antihypertensive agents in African Hypertensive patients (NOAAH) trial, Odili and colleagues compared the BP-lowering efficacy of a combination of newer (without a diuretic) versus older (with a diuretic) antihypertensive agents in black patients with hypertension born and living in sub-Saharan Africa \[[@CR62]\]. The NOAAH study compared two SPCs for control of BP in African patients 30--69 years of age (mean age 51 years) with stage 1 or 2 hypertension (systolic/diastolic BP: 140--179/90--109 mmHg) and no more than two additional risk factors. After a 4-week wash-out period, 140 patients were randomized to once-daily bisoprolol/hydrochlorothiazide (HCTZ) 5/6.25 mg or amlodipine/valsartan 5/160 mg, with permitted up-titration of the bisoprolol and amlodipine doses to 10 mg to achieve BP \<140/90 mmHg \[[@CR53]\]. At randomization, the bisoprolol/HCTZ and amlodipine/valsartan groups were similar with respect to demographic characteristics, and the overall combined systolic/diastolic BP was 153.9/91.5 mmHg. After randomization, in both groups combined, BP dropped by 18.2/10.1 mmHg at week 2 (*n* = 122), 19.4/11.2 mmHg at week 4 (*n* = 109), 22.4/12.2 mmHg at week 8 (*n* = 57), and 25.8/15.2 mmHg at week 12 (*n* = 49). The BP control rate of \<140/90 mmHg was \>65 % by week 2. Thus, NOAAH confirmed that SPC therapy can achieve BP control quickly in black patients born and living in sub-Saharan Africa and that randomized clinical trials of antihypertensive drugs in this indigenous population are feasible \[[@CR53]\].

Although most studies have been done in blacks of African descent in the USA, there are data suggesting that an increase in the incidence of hypertension in blacks living in sub-Saharan Africa is leading to an increase in heart failure and CVD. In a recent (2012) study by Damasceno and colleagues, a prospective, multicenter, observational survey collected data on patients with acute heart failure (AHF) who had been admitted to 12 university hospitals in nine African countries (Sub-Saharan Africa Survey of Heart Failure \[THESUS-HF\]) \[[@CR63]\]. The THESUS-HF survey enrolled 1,006 patients presenting with AHF between 2007 and 2010; mean age was 52.3 years, 50.8 % were women, the predominant race was black African (98.5 %), and mean left ventricular ejection fraction was 39.5 %. The most common reason for heart failure was noted to be hypertension (45.4 %), while rheumatic heart disease (14.3 %) and ischemic heart disease (7.7 %) were not as commonly documented causes of AHF. The median hospital stay was 7 days, with an in-hospital mortality of 4.2 % and an estimated 180-day mortality of 17.8 % (95 % confidence interval 15.4--20.6). Overall, the THESUS-HF survey demonstrated that in African patients, AHF is primarily due to a non-ischemic cause, most commonly hypertension; occurs equally among genders, usually in middle-aged adults; and is associated with high mortality.

African Americans {#Sec10}
-----------------

The EXforge evaluation in Stage Two hypertensives of AfricaN Descent (EX-STAND) study was a 12-week, multicenter, double-blind, prospective, parallel-group trial of 572 black patients (mean age 53 years) with stage 2 hypertension (mean sitting systolic blood pressure \[MSSBP\] 160--199 mmHg) in the USA \[[@CR54]\]. Patients were randomized to either combination amlodipine/valsartan 5/160 mg or amlodipine 5-mg monotherapy. At 2 weeks, doses were force-titrated to 10/160 mg and 10 mg, respectively. At 4 weeks, there was optional up-titration to 10/320 mg in the combination-therapy arm if MSSBP was ≥130 mmHg. The combination of amlodipine/valsartan attained greater and faster reductions in BP: by week 8, combination amlodipine/valsartan significantly lowered MSSBP more than monotherapy (33.3 vs. 26.6 mmHg; *P* \< 0.0001). A BP goal of \<140/90 mmHg was achieved by 49.8 and 30.2 % of patients, respectively (*P* \< 0.0001).

A subgroup analysis of two 8-week, multicenter, randomized, double-blind, placebo-controlled studies (*n* = 3,161) included 2,508 white patients (mean age 56 years) and 201 black patients (mean age 50 years) with stage 1 or 2 hypertension (mean sitting diastolic blood pressure \[MSDBP\] 95--109 mmHg) \[[@CR55]\]. Patients received amlodipine monotherapy, valsartan monotherapy, or a combination of these agents at various dosages (Table [1](#Tab1){ref-type="table"}). Combination therapy was significantly more effective in lowering BP than treatment with the respective monotherapies. In blacks, the greatest reduction in MSDBP was seen with amlodipine/valsartan 5/320 mg (17.9 mmHg), which was consistent with the reduction seen in whites (15.5 mmHg).

In a post hoc analysis of patients with hypertension enrolled in a 12-week, multicenter, randomized, double-blind clinical trial (EXforge TaRget Achievement \[EXTRA\]), treatment responses with combination amlodipine/valsartan 10/320 mg versus amlodipine/valsartan 5/160 mg were evaluated among a diverse cohort (474 white, 198 black, and 165 Hispanic individuals ranging in age from a mean of 51--57 years) \[[@CR42]\]. Patients were treatment naïve or non-responders (MSSBP 150--199 mmHg) to angiotensin receptor blocker monotherapy (other than valsartan). Regardless of race or ethnic background, results demonstrated that more intensive dosage treatment provided greater BP lowering versus moderate treatment. In blacks, moderate treatment for 4 weeks (before addition of HCTZ) lowered MSSBP by 18.1 mmHg and allowed 26.9 % of patients to achieve BP goal (\<140/90 mmHg), whereas intensive treatment lowered MSSBP by 20.4 mmHg with 37.1 % of patients attaining BP goal (*P* = not significant/*P* \< 0.01). Further improvement in BP was seen with the addition of HCTZ.

Across all studies, the combination of amlodipine/valsartan was well tolerated (Table [1](#Tab1){ref-type="table"}). Peripheral edema was reported at an incidence ranging from 2.1 to 12.6 % in the black population, which was within the range reported in control patients (9.5--15.4 %). Other adverse events reported among blacks treated with amlodipine/valsartan included headache (3.2--6.1 vs. 5.3--7.7 % in controls) and dizziness (2.1--6.7 vs. 2.5 % in controls).

Hispanics/Latinos {#Sec11}
-----------------

In the EXforge EFFicacy and Control in Treatment of Stage 2 hypertension (EX-EFFeCTS) study, the efficacy and safety of combination amlodipine/valsartan versus amlodipine alone were compared in 646 patients (mean age 58 years) with stage 2 hypertension (MSSBP 160--199 mmHg) \[[@CR59]\]. In this 8-week, multicenter, randomized, double-blind study, approximately one third of the study population (*n* = 224; 34.7 %) was of Hispanic/Latino ethnicity. The initiating doses were amlodipine/valsartan 5/160 mg or amlodipine 5 mg for 2 weeks, with force-titration to amlodipine/valsartan 10/160 mg or amlodipine 10 mg, respectively, for an additional 6 weeks. At 4 weeks (primary endpoint), MSSBP demonstrated an improvement in Hispanic/Latino patients receiving amlodipine/valsartan compared with those receiving amlodipine alone (−29.1 vs. −23.0 mmHg; *P* \< 0.05). An MSSBP \<140 mmHg was achieved by 55.1 and 35.8 % of Hispanic/Latino patients, respectively (*P* value not reported).

The previously mentioned post hoc analysis by Ofili and colleagues included 165 (22.7 %) Hispanic patients \[[@CR42]\]. In this population, treatment with combination amlodipine/valsartan for 4 weeks lowered MSSBP by 17.5 mmHg (moderate treatment) or 23.4 mmHg (intensive treatment) (*P* \< 0.01). Corresponding BP control rates were 33.3 and 54.8 % (*P* \< 0.01). As in black people, the addition of HCTZ provided further antihypertensive efficacy.

In both of the above studies, efficacy results in Hispanic/Latino patients were similar to those seen for other race groups and the overall population (Table [1](#Tab1){ref-type="table"}). In addition, the combination of amlodipine/valsartan was well tolerated, providing support for use of this regimen in Hispanic/Latino patients. The most commonly reported adverse event was peripheral edema: 8.2 % with the intensive regimen and 2.5 % with the moderate regimen in one study and 12.8 % with combination therapy versus 17.6 % with amlodipine monotherapy in the other study. Across both studies, headache was reported by 2.4--4.9 % of patients receiving amlodipine/valsartan and 3.1 % of patients receiving amlodipine alone.

Asians {#Sec12}
------

Due to less-robust data in Asian Americans, clinical data are discussed for non-American Asian cohorts. Recently, an open-label, observational, non-interventional, surveillance study was designed to evaluate the safety and effectiveness of the amlodipine/valsartan combination \[[@CR56]\]. There were 2,729 participants with systolic BP \>140 mmHg and/or diastolic BP \>90 mmHg from 298 centers around the world, including China, Malaysia, Pakistan, Bangladesh, Egypt, and Russia. The cohort was composed of 54.5 % men, 54.2 % Asian, and 44.6 % white. Mean age was 57.9 years, baseline BP was 163.1/96.2 mmHg, and 86.5 % had prior hypertension therapy that was discontinued. During the 12 weeks of treatment with amlodipine/valsartan, there was a significant systolic/diastolic BP reduction of 33.2/16.9 mmHg (*P* \< 0.0001), resulting in a substantially lower final BP reading of 129.9/79.3 mmHg. Additionally, Chazova and colleagues \[[@CR56]\] demonstrated a dose-dependent effect with amlodipine/valsartan where the smallest BP reduction was 29.2/15.1 mmHg with the 5/80-mg dose (*P* \< 0.0001) and the greatest BP reduction was 43.6/22.4 mmHg with the 10/160-mg dose (*P* \< 0.0001). BP lowering was linked to the severity of baseline BP levels.

In an 8-week, multicenter, randomized, double-blind trial, Ke and colleagues \[[@CR57]\] studied the effects of the SPC of amlodipine/valsartan compared with amlodipine alone in an Asian hypertensive population that was non-responsive (MSDBP 90--109 mmHg) to amlodipine 5-mg monotherapy. Baseline characteristics were similar between treatment groups: the majority of patients were male (65.1 %) and Chinese (86.4 %); mean age was 53.8 years; and mean seated systolic/diastolic BP was 139.5/94.5 mmHg. After a 1--4-week washout period, a total of 698 patients were randomized to either amlodipine/valsartan 5/80 mg or amlodipine 5 mg. Results showed that the reduction in systolic/diastolic BP at the week 8 endpoint was significantly greater with amlodipine/valsartan than with amlodipine (11.4/9.7 vs. 7.4/7.1 mmHg; *P* \< 0.0001), with a correspondingly higher BP-control rate (\<140/90 mmHg): 69.2 versus 57.6 %; *P* = 0.0013.

Huang and colleagues \[[@CR58]\] evaluated the efficacy of the SPC of amlodipine/valsartan in another 8-week, randomized, double-blind study of 918 Asian patients (mean age 52 years) with stage 1 or 2 hypertension (MSDBP 90--109 mmHg) from 30 centers in Asia who were not responding to valsartan 80-mg monotherapy. The patients were randomized to receive amlodipine/valsartan 5/80 mg (*n* = 308), valsartan 80 mg (*n* = 307), or valsartan 160 mg (*n* = 303). Results at the week 8 endpoint revealed reductions in BP of 12.5/10.8 mmHg for amlodipine/valsartan 5/80 mg, which were significantly greater than those for valsartan 80 mg (6.0/6.3 mmHg) or valsartan 160 mg (7.7/7.2 mmHg) (*P* \< 0.0001). Regardless of baseline BP, at the week 8 endpoint, a significant proportion of patients achieved BP control with amlodipine/valsartan 5/80 mg compared with the valsartan monotherapies (Table [1](#Tab1){ref-type="table"}; *P* \< 0.01 for both comparisons).

As shown in Table [1](#Tab1){ref-type="table"}, the combination of amlodipine/valsartan was well tolerated across each of the above studies. Across the three studies identified in the Asian population assessments, the most commonly reported adverse event was hyperlipidemia (up to 4.3 % of patients on amlodipine/valsartan vs. 3.2 % on amlodipine monotherapy and 4.2--5.0 % on valsartan monotherapy). Dizziness was the second most common adverse event, reported in 1.4--2.9 % of patients on combination therapy and 1.0--2.0 % on monotherapy.

Conclusions {#Sec13}
===========

Hypertension and its related morbidity and mortality affect a disproportionate number of black patients compared with white patients. Blacks, Hispanics/Latinos, and Asians especially need effective hypertension treatment and control, considering their high prevalence of comorbidities, including obesity, diabetes, and metabolic syndrome. Such high-risk patients are good candidates for RAAS-inhibitor-based combination therapy, including a thiazide-type diuretic or long-acting calcium channel blocker. Adherence and persistence to antihypertensive medication remain suboptimal, including in these non-white populations, with evidence suggesting improvement with the use of SPC therapy. Results of clinical trials in blacks, Hispanics/Latinos, and Asians with stage 1 or 2 hypertension show that treatment with the combination of a dihydropyridine calcium channel blocker plus RAAS blocker (e.g., amlodipine/valsartan) is a reasonable choice for initial therapy or in patients who fail to respond to monotherapy. These drug classes have complementary mechanisms of action and, when used concomitantly, the magnitude of BP lowering in these non-white populations is generally comparable with that seen in non-Hispanic white patients. Although the clinical trial evidence is not examined in this review, if necessary, a diuretic can be added to the amlodipine/valsartan combination to further reduce BP, without compromising safety and tolerability \[[@CR64], [@CR65]\].

Although the focus of this article is on combination calcium channel blocker/RAAS blocker therapy (particularly, amlodipine/valsartan), treatment with a thiazide-type diuretic plus RAAS blocker is another effective approach for the treatment of hypertension, including in non-white hypertensive patients \[[@CR66], [@CR67]\]. The main concern with using thiazide-type diuretics has been tolerability, although lower doses are generally well tolerated \[[@CR68]\]. Some evidence suggests that calcium channel blockers may provide greater regression of organ damage than thiazide diuretics, when used in combination with RAAS blockers \[[@CR69], [@CR70]\], and that combination calcium channel blocker/RAAS blocker therapy may reduce the risk of new-onset diabetes in hypertensive patients with metabolic syndrome \[[@CR71], [@CR72]\]. Furthermore, results of the Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH) trial suggest that treatment with a calcium channel blocker plus RAAS blocker, relative to a thiazide diuretic plus RAAS blocker, may confer greater protection from cardiovascular events and renal disease progression in high-risk hypertensive patients \[[@CR73], [@CR74]\]. Although the majority of patients enrolled in ACCOMPLISH were white, they had a high incidence of cardiovascular risk factors (e.g., diabetes \[60 %\], dyslipidemia \[74 %\], obesity \[mean BMI 31 kg/m^2^\]) that are common in blacks, Hispanics/Latinos, and Asians. Further comparative studies are needed to determine optimal antihypertensive combinations in these minority populations.

Our findings are not unique to combination amlodipine/valsartan therapy. Similar results have been reported with other amlodipine/angiotensin receptor blocker SPC therapies in blacks and Hispanics/Latinos (e.g., amlodipine/olmesartan \[[@CR75]\], amlodipine/telmisartan \[[@CR76]\]), although data in Asians are lacking with these other combinations. Of note, because of acculturation and certain health behaviors (e.g., diet, physical activity), it is not known whether the literature findings reported in Asian patients can be generalized to the Asian American population. Kaplan and colleagues \[[@CR77]\] reported that the prevalence of hypertension among Asian immigrants increased with increasing length of residence in Canada, from 3 % (0--4 years) to 7 % (5--9 years) to 13 % (10 or more years). A similar association was reported in a multiethnic cohort (white, black, Latino, and Asian) living in the USA, independent of confounders such as age, gender, race/ethnicity, level of education, smoking, alcohol intake, physical activity, BMI, and history of diabetes \[[@CR78]\]. In addition, although BP reductions appear robust with combination amlodipine/valsartan, outcomes data comparing this treatment approach with other combination regimens are not available. Thus, the optimal cardiovascular outcome benefits during management of patients with amlodipine/valsartan and similar combinations cannot be determined at this time. Lastly, it is important to note that pharmacological therapy is not a substitute for lifestyle changes. Sodium restriction, smoking cessation, weight reduction, moderation of alcohol consumption, and a diet rich in fruits, vegetables, and low-fat dairy products have been shown to reduce BP, and should be implemented in all patients including those who require antihypertensive drug therapy \[[@CR4], [@CR79]\].
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